SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
March 14, 2024 05:00 ET
|
S. M. Discovery Group (SMDG)
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024
March 04, 2024 10:00 ET
|
Baylor Genetics
Researchers present abstracts and poster sessions showcasing research and clinical solutions.
Joint session planned with Illumina.
For Rare Liver Disease Patients, Care Transitions Pose Yet Another Risk
February 01, 2024 08:00 ET
|
Global Liver Institute
Washington, D.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Today marks the start of Global Liver Institute’s (GLI) 2024 #RareAware campaign, which calls attention to the more than 100 rare liver diseases...
Baylor Genetics Chief Medical Officer Christine Eng, M.D., Shares Sequencing Approaches for Undiagnosed Patients at Precision Medicine World Conference 2024
January 23, 2024 09:00 ET
|
Baylor Genetics
Showcase Presentation to Include Case Examples from NIH’s Undiagnosed Diseases Network (UDN)
Myasthenia Gravis Treatment Market Will Experience Growth, Reaching US$4.1 Billion by the End of 2030, Predicts Persistence Market Research
January 23, 2024 01:45 ET
|
Persistence Market Research
New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Myasthenia Gravis Treatment Market Poised for Steady Growth, driven by Innovation and Rising Awareness The global market for myasthenia gravis (MG)...
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
November 09, 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Baylor Genetics to Present Scientific Research Findings at Upcoming NORD, NSGC and ASHG Conferences
October 02, 2023 10:00 ET
|
Baylor Genetics
Baylor Genetics to present at three top genetic conferences on WES, WGS, carrier screening and non-invasive prenatal testing
Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
August 31, 2023 07:00 ET
|
Jnana Therapeutics, Inc.
JNT-517 demonstrated sustained, dose-dependent pharmacodynamic effects and was safe and well tolerated in healthy volunteers Phase 1b study is ongoing in individuals with PKU BOSTON, Aug. 31, 2023 ...
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 in Individuals with PKU
August 09, 2023 07:00 ET
|
Jnana Therapeutics, Inc.
JNT-517 is a Potential First-in-Class Oral Treatment for PKU; Phase 1b Study Follows Positive Clinical Proof of Mechanism Data in Healthy Individuals Upcoming Oral Presentation of Phase 1a Study...
Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain
May 17, 2023 11:24 ET
|
Visiongain Reports Ltd
As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033. Visiongain has...